Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 18/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269340 | 0.94 | PDE2A (0.44) | PDE2AMAPK1RPS6KA1SCN10A | |
| SCHEMBL263422 | 0.87 | PDE2A (0.46) | PDE2A | |
| SCHEMBL269762 | 0.81 | PDE2A (0.45) | PDE2A | |
| SCHEMBL264134 | 0.75 | NR1H4 (0.47) | PDE2AMAPK1 | |
| SCHEMBL264226 | 0.74 | MEN1 (0.44) | SCN10A | |
| SCHEMBL283861 | 0.69 | MEN1 (0.42) | SCN10A | |
| SCHEMBL1643131 | 0.69 | PDE2A (0.45) | PDE2A | |
| SCHEMBL25497861 | 0.68 | MEN1 (0.47) | SCN10A | |
| SCHEMBL2939106 | 0.68 | PDE2A (0.48) | PDE2ASCN10A | |
| SCHEMBL263432 | 0.68 | MAPK1 (0.42) | PDE2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | PDE2A 2484/4885MAPK1 1388/4885RPS6KA1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.